Top

Published in:

01-06-2016 | Invited article

The spectrum of renal cell carcinoma in adults

Authors: Lakshmi Ananthakrishnan, Payal Kapur, John R. Leyendecker

Published in: Abdominal Radiology | Issue 6/2016

Abstract

The spectrum of renal cell carcinoma (RCC) includes many neoplasms with distinct cytogenetics, biologic behaviors, and imaging appearances. The advent of molecular therapies targeting different tumor types, new insights into the relative roles of biopsy and surveillance for small incidental tumors, and a growing array of nephron-sparing interventions have altered management of RCC. Similarly, the role of the radiologist is changing, and it is becoming increasingly important for radiologists to familiarize themselves with the various types of RCC. This article introduces the reader to the common and uncommon recognized types of renal cell carcinoma and discusses how these neoplasms differ in imaging appearance and behavior.

Srigley JR, Delahunt B, Eble JN, et al. (2013) The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 37(10):1469–1489. doi:10.1097/PAS.0b013e318299f2d1 CrossRefPubMed

Campbell N, Rosenkrantz AB, Pedrosa I (2014) MRI phenotype in renal cancer: is it clinically relevant? Top Magn Reson Imaging : TMRI 23(2):95–115. doi:10.1097/RMR.0000000000000019 CrossRefPubMedPubMedCentral

Escudier B, Eisen T, Porta C, et al. (2012) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol . doi:10.1093/annonc/mds227

Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press

Bostwick DG, Murphy GP (1998) Diagnosis and prognosis of renal cell carcinoma: highlights from an international consensus workshop. Semin Urol Oncol 16(1):46–52PubMed

Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. AmJ Surg Pathol 27(5):612–624CrossRef

Adeniran AJ, Shuch B, Humphrey PA (2015) Hereditary renal cell carcinoma syndromes: clinical, pathologic, and genetic features. AmJ Surg Pathol 39(12):e1–e18. doi:10.1097/pas.0000000000000562 CrossRef

Allen BC, Tirman P, Jennings Clingan M, et al. (2014) Characterizing solid renal neoplasms with MRI in adults. Abdom Imaging 39(2):358–387. doi:10.1007/s00261-014-0074-4 CrossRefPubMed

Sukosd F, Kuroda N, Beothe T, Kaur AP, Kovacs G (2003) Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res 63(2):455–457PubMed

10.

Varela I, Tarpey P, Raine K, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331):539–542. doi:10.1038/nature09639 CrossRefPubMedPubMedCentral

11.

Brugarolas J (2014) Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 32(18):1968–1976. doi:10.1200/jco.2012.45.2003 CrossRefPubMedPubMedCentral

12.

Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. (2012) BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 44(7):751–759. doi:10.1038/ng.2323 CrossRefPubMedPubMedCentral

13.

Kandoth C, McLellan MD, Vandin F, et al. (2013) Mutational landscape and significance across 12 major cancer types. Nature 502(7471):333–339. doi:10.1038/nature12634 CrossRefPubMedPubMedCentral

14.

Gerlinger M, Rowan AJ, Horswell S, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892. doi:10.1056/NEJMoa1113205 CrossRefPubMedPubMedCentral

15.

Jinzaki M, Tanimoto A, Mukai M, et al. (2000) Double-phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr 24(6):835–842CrossRefPubMed

16.

Herts BR, Coll DM, Novick AC, et al. (2002) Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR Am J Roentgenol 178(2):367–372. doi:10.2214/ajr.178.2.1780367 CrossRefPubMed

17.

Jung SC, Cho JY, Kim SH (2012) Subtype differentiation of small renal cell carcinomas on three-phase MDCT: usefulness of the measurement of degree and heterogeneity of enhancement. Acta Radiol (Stockholm, Sweden: 1987) 53(1):112–118. doi:10.1258/ar.2011.110221

18.

Mileto A, Marin D, Alfaro-Cordoba M, et al. (2014) Iodine quantification to distinguish clear cell from papillary renal cell carcinoma at dual-energy multidetector CT: a multireader diagnostic performance study. Radiology 273(3):813–820. doi:10.1148/radiol.14140171 CrossRefPubMed

19.

Zhang J, Lefkowitz RA, Ishill NM, et al. (2007) Solid renal cortical tumors: differentiation with CT. Radiology 244(2):494–504. doi:10.1148/radiol.2442060927 CrossRefPubMed

20.

Sun MR, Ngo L, Genega EM, et al. (2009) Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes–correlation with pathologic findings. Radiology 250(3):793–802. doi:10.1148/radiol.2503080995 CrossRefPubMed

21.

Pedrosa I, Chou MT, Ngo L, et al. (2008) MR classification of renal masses with pathologic correlation. Eur Radiol 18(2):365–375. doi:10.1007/s00330-007-0757-0 CrossRefPubMed

22.

Pedrosa I, Sun MR, Spencer M, et al. (2008) MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics 28(4):985–1003. doi:10.1148/rg.284065018 CrossRefPubMed

23.

Jhaveri KS, Elmi A, Hosseini-Nik H, et al. (2015) Predictive Value of Chemical-Shift MRI in Distinguishing Clear Cell Renal Cell Carcinoma From Non-Clear Cell Renal Cell Carcinoma and Minimal-Fat Angiomyolipoma. AJR Am J Roentgenol 205(1):W79–W86. doi:10.2214/ajr.14.13245 CrossRefPubMed

24.

Choi YA, Kim CK, Park SY, Cho SW, Park BK (2014) Subtype differentiation of renal cell carcinoma using diffusion-weighted and blood oxygenation level-dependent MRI. AJR Am J Roentgenol 203(1):W78–W84. doi:10.2214/ajr.13.11551 CrossRefPubMed

25.

Hindman N, Ngo L, Genega EM, et al. (2012) Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? Radiology 265(2):468–477. doi:10.1148/radiol.12112087 CrossRefPubMedPubMedCentral

26.

Sasiwimonphan K, Takahashi N, Leibovich BC, et al. (2012) Small (< 4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. Radiology 263(1):160–168. doi:10.1148/radiol.12111205 CrossRefPubMed

27.

Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG (2008) Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 112(7):1480–1488. doi:10.1002/cncr.23322 CrossRefPubMed

28.

Mai KT, Landry DC, Robertson SJ, et al. (2001) A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor. Pathol Res Pract 197(10):671–675. doi:10.1078/0344-0338-00144 CrossRefPubMed

29.

Swanson DA, Orovan WL, Johnson DE, Giacco G (1981) Osseous metastases secondary to renal cell carcinoma. Urology 18(6):556–561CrossRefPubMed

30.

Salapura V, Zupan I, Seruga B, Gasljevic G, Kavcic P (2014) Osteoblastic bone metastases from renal cell carcinoma. Radiol Oncol 48(3):243–246. doi:10.2478/raon-2013-0034 CrossRefPubMedPubMedCentral

31.

Kim JK, Kim TK, Ahn HJ, et al. (2002) Differentiation of Subtypes of Renal Cell Carcinoma on Helical CT Scans. Am J Roentgenol 178(6):1499–1506. doi:10.2214/ajr.178.6.1781499 CrossRef

32.

Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10(6):537–544PubMed

33.

Pignot G, Elie C, Conquy S, et al. (2007) Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 69(2):230–235. doi:10.1016/j.urology.2006.09.052 CrossRefPubMed

34.

Leroy X, Zini L, Leteurtre E, et al. (2002) Morphologic subtyping of papillary renal cell carcinoma: correlation with prognosis and differential expression of MUC1 between the two subtypes. Mod Pathol 15(11):1126–1130. doi:10.1097/01.mp.0000036346.88874.25 CrossRefPubMed

35.

Egbert ND, Caoili EM, Cohan RH, et al. (2013) Differentiation of papillary renal cell carcinoma subtypes on CT and MRI. AJR Am J Roentgenol 201(2):347–355. doi:10.2214/AJR.12.9451 CrossRefPubMed

36.

Pierorazio PM, Hyams ES, Tsai S, et al. (2013) Multiphasic enhancement patterns of small renal masses (≤4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma. Urology 81(6):1265–1271. doi:10.1016/j.urology.2012.12.049 CrossRefPubMedPubMedCentral

37.

Silverman SG, Mortele KJ, Tuncali K, Jinzaki M, Cibas ES (2007) Hyperattenuating renal masses: etiologies, pathogenesis, and imaging evaluation. Radiographics 27(4):1131–1143. doi:10.1148/rg.274065147 CrossRefPubMed

38.

Suh M, Coakley FV, Qayyum A, et al. (2003) Distinction of renal cell carcinomas from high-attenuation renal cysts at portal venous phase contrast-enhanced CT. Radiology 228(2):330–334. doi:10.1148/radiol.2282020922 CrossRefPubMed

39.

Oliva MR, Glickman JN, Zou KH, et al. (2009) Renal cell carcinoma: t1 and t2 signal intensity characteristics of papillary and clear cell types correlated with pathology. AJR Am J Roentgenol 192(6):1524–1530. doi:10.2214/ajr.08.1727 CrossRefPubMed

40.

Childs DD, Clingan MJ, Zagoria RJ, et al. (2014) In-phase signal intensity loss in solid renal masses on dual-echo gradient-echo MRI: association with malignancy and pathologic classification. AJR Am J Roentgenol 203(4):W421–W428. doi:10.2214/ajr.13.11113 CrossRefPubMed

41.

Lanzman RS, Robson PM, Sun MR, et al. (2012) Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings. Radiology 265(3):799–808. doi:10.1148/radiol.12112260 CrossRefPubMedPubMedCentral

42.

Vikram R, Ng CS, Tamboli P, et al. (2009) Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics 29(3):741–754 (discussion 755–747). doi:10.1148/rg.293085190 CrossRefPubMed

43.

Lay AH, Faddegon S, Olweny EO, et al. (2015) Oncologic Efficacy of Radio Frequency Ablation for Small Renal Masses: clear Cell vs Papillary Subtype. J Urol . doi:10.1016/j.juro.2015.03.115

44.

Courthod G, Tucci M, Di Maio M, Scagliotti GV (2015) Papillary renal cell carcinoma: a review of the current therapeutic landscape. Crit Rev Oncol/Hematol 96(1):100–112. doi:10.1016/j.critrevonc.2015.05.008 CrossRef

45.

Gurel S, Narra V, Elsayes KM, et al. (2013) Subtypes of renal cell carcinoma: MRI and pathological features. Diagn Interv Radiol (Ankara, Turkey) 19(4):304–311. doi:10.5152/dir.2013.147

46.

Vera-Badillo FE, Conde E, Duran I (2012) Chromophobe renal cell carcinoma: a review of an uncommon entity. Int J Urol 19(10):894–900. doi:10.1111/j.1442-2042.2012.03079.x CrossRefPubMed

47.

Rosenkrantz AB, Hindman N, Fitzgerald EF, et al. (2010) MRI features of renal oncocytoma and chromophobe renal cell carcinoma. AJR Am J Roentgenol 195(6):W421–W427. doi:10.2214/AJR.10.4718 CrossRefPubMed

48.

Lee-Felker SA, Felker ER, Tan N, et al. (2014) Qualitative and quantitative MDCT features for differentiating clear cell renal cell carcinoma from other solid renal cortical masses. AJR Am J Roentgenol 203(5):W516–W524. doi:10.2214/AJR.14.12460 CrossRefPubMed

49.

Kondo T, Nakazawa H, Sakai F, et al. (2004) Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: a retrospective analysis on computed tomography and magnetic resonance imaging studies. Int J Urol 11(10):817–824. doi:10.1111/j.1442-2042.2004.00907.x CrossRefPubMed

50.

Hindman NM, Bosniak MA, Rosenkrantz AB, Lee-Felker S, Melamed J (2012) Multilocular cystic renal cell carcinoma: comparison of imaging and pathologic findings. AJR Am J Roentgenol 198(1):W20–W26. doi:10.2214/AJR.11.6762 CrossRefPubMed

51.

Prasad SR, Humphrey PA, Catena JR, et al. (2006) Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 26(6):1795–1806 (discussion 1806-1710). doi:10.1148/rg.266065010 CrossRefPubMed

52.

Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (2006) 2004 WHO classification of the renal tumors of the adults. Eur Urol 49(5):798–805. doi:10.1016/j.eururo.2005.11.035 CrossRefPubMed

53.

Aubert S, Zini L, Delomez J, et al. (2005) Cystic renal cell carcinomas in adults. Is preoperative recognition of multilocular cystic renal cell carcinoma possible? J Urol 174(6):2115–2119. doi:10.1097/01.ju.0000181210.72528.ab CrossRefPubMed

54.

Algaba F, Akaza H, Lopez-Beltran A, et al. (2011) Current pathology keys of renal cell carcinoma. Eur Urol 60(4):634–643. doi:10.1016/j.eururo.2011.06.047 CrossRefPubMed

55.

Pickhardt PJ, Siegel CL, McLarney JK (2001) Collecting duct carcinoma of the kidney: are imaging findings suggestive of the diagnosis? AJR Am J Roentgenol 176(3):627–633. doi:10.2214/ajr.176.3.1760627 CrossRefPubMed

56.

Shanbhogue AK, Vikram R, Paspulati RM, et al. (2012) Rare (< 1%) histological subtypes of renal cell carcinoma: an update. Abdom Imaging 37(5):861–872. doi:10.1007/s00261-011-9810-1 CrossRefPubMed

57.

Kennedy SM, Merino MJ, Linehan WM, et al. (1990) Collecting duct carcinoma of the kidney. Hum Pathol 21(4):449–456CrossRefPubMed

58.

Yoon SK, Nam KJ, Rha SH, et al. (2006) Collecting duct carcinoma of the kidney: CT and pathologic correlation. Eur J Radiol 57(3):453–460. doi:10.1016/j.ejrad.2005.09.009 CrossRefPubMed

59.

Tokuda N, Naito S, Matsuzaki O, et al. (2006) Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 176(1):40–43. doi:10.1016/s0022-5347(06)00502-7 CrossRefPubMed

60.

Srigley JR, Eble JN (1998) Collecting duct carcinoma of kidney. Semin Diagn Pathol 15(1):54–67PubMed

61.

Blitman NM, Berkenblit RG, Rozenblit AM, Levin TL (2005) Renal medullary carcinoma: CT and MRI features. AJR Am J Roentgenol 185(1):268–272. doi:10.2214/ajr.185.1.01850268 CrossRefPubMed

62.

Simpson L, He X, Pins M, et al. (2005) Renal medullary carcinoma and ABL gene amplification. J Urol 173(6):1883–1888. doi:10.1097/01.ju.0000158448.56888.09 CrossRefPubMed

63.

Pirich LM, Chou P, Walterhouse DO (1999) Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma. J Pediatr Hematol/Oncol 21(1):67–69CrossRef

64.

Hirsch MS, Signoretti S, Dal Cin P (2015) Adult Renal Cell Carcinoma: A Review of Established Entities from Morphology to Molecular Genetics. Surg Pathol Clin 8(4):587–621. doi:10.1016/j.path.2015.09.003 CrossRefPubMed

65.

Argani P, Ladanyi M (2005) Translocation carcinomas of the kidney. Clin Lab Med 25(2):363–378. doi:10.1016/j.cll.2005.01.008 CrossRefPubMed

66.

Camparo P, Vasiliu V, Molinie V, et al. (2008) Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 32(5):656–670. doi:10.1097/PAS.0b013e3181609914 CrossRefPubMed

67.

Argani P, Lal P, Hutchinson B, et al. (2003) Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 27(6):750–761CrossRefPubMed

68.

Koo HJ, Choi HJ, Kim MH, Cho KS (2013) Radiologic-pathologic correlation of renal cell carcinoma associated with Xp11.2 translocation. Acta radiologica (Stockholm, Sweden : 1987) 54 (7):827–834. doi:10.1177/0284185113484019

69.

Zhu QQ, Wang ZQ, Zhu WR, Chen WX, Wu JT (2013) The multislice CT findings of renal carcinoma associated with XP11.2 translocation/TFE gene fusion and collecting duct carcinoma. Acta Radiol (Stockholm, Sweden: 1987) 54(3):355–362. doi:10.1258/ar.2012.120255

70.

Woo S, Kim SY, Lee MS, et al. (2015) MDCT findings of renal cell carcinoma associated with Xp11.2 translocation and TFE3 gene fusion and papillary renal cell carcinoma. AJR. Am J Roentgenol 204(3):542–549. doi:10.2214/ajr.14.12950 CrossRef

71.

Kenney PA, Vikram R, Prasad SR, et al. (2015) Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int 116(1):85–92. doi:10.1111/bju.12992 CrossRefPubMed

72.

Sahni VA, Hirsch MS, Sadow CA, Silverman SG (2012) Mucinous tubular and spindle cell carcinoma of the kidney: imaging features. Cancer Imaging 12:66–71. doi:10.1102/1470-7330.2012.0008 CrossRefPubMed

73.

Rakozy C, Schmahl GE, Bogner S, Storkel S (2002) Low-grade tubular-mucinous renal neoplasms: morphologic, immunohistochemical, and genetic features. Mod Pathol 15(11):1162–1171. doi:10.1097/01.mp.0000031709.40712.46 CrossRefPubMed

74.

Dhillon J, Amin MB, Selbs E, et al. (2009) Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol 33(1):44–49. doi:10.1097/PAS.0b013e3181829ed5 CrossRefPubMed

75.

Kuroda N, Hes O, Michal M, et al. (2008) Mucinous tubular and spindle cell carcinoma with Fuhrman nuclear grade 3: a histological, immunohistochemical, ultrastructural and FISH study. Histol Histopathol 23(12):1517–1523PubMed

76.

Medeiros LJ, Palmedo G, Krigman HR, Kovacs G, Beckwith JB (1999) Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. Am J Surg Pathol 23(7):772–780CrossRefPubMed

77.

Jewett MA, Mattar K, Basiuk J, et al. (2011) Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 60(1):39–44. doi:10.1016/j.eururo.2011.03.030 CrossRefPubMed

78.

Frank I, Blute ML, Cheville JC, et al. (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170(6 Pt 1):2217–2220. doi:10.1097/01.ju.0000095475.12515.5e CrossRefPubMed

79.

Rothman J, Egleston B, Wong YN, et al. (2009) Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol 181(1):29–33 (discussion 33–24). doi:10.1016/j.juro.2008.09.009 CrossRefPubMedPubMedCentral

80.

Silverman SG, Israel GM, Trinh QD (2015) Incompletely characterized incidental renal masses: emerging data support conservative management. Radiology 275(1):28–42. doi:10.1148/radiol.14141144 CrossRefPubMed

81.

Silverman SG, Gan YU, Mortele KJ, Tuncali K, Cibas ES (2006) Renal masses in the adult patient: the role of percutaneous biopsy. Radiology 240(1):6–22. doi:10.1148/radiol.2401050061 CrossRefPubMed

82.

Silverman SG, Israel GM, Herts BR, Richie JP (2008) Management of the incidental renal mass. Radiology 249(1):16–31. doi:10.1148/radiol.2491070783 CrossRefPubMed

83.

Sahni VA, Ly A, Silverman SG (2011) Usefulness of percutaneous biopsy in diagnosing benign renal masses that mimic malignancy. Abdom Imaging 36(1):91–101. doi:10.1007/s00261-009-9597-5 CrossRefPubMed

84.

Tan HJ, Jacobs BL, Hafez KS, et al. (2012) Understanding the role of percutaneous biopsy in the management of patients with a small renal mass. Urology 79(2):372–377. doi:10.1016/j.urology.2011.09.050 CrossRefPubMed

85.

Tang S, Li JH, Lui SL, et al. (2002) Free-hand, ultrasound-guided percutaneous renal biopsy: experience from a single operator. Eur J Radiol 41(1):65–69CrossRefPubMed

86.

Pandharipande PV, Gervais DA, Hartman RI, et al. (2010) Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis. Radiology 256(3):836–846. doi:10.1148/radiol.10092013 CrossRefPubMedPubMedCentral

87.

Patel N, Cranston D, Akhtar MZ, et al. (2012) Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int 110(9):1270–1275. doi:10.1111/j.1464-410X.2012.11130.x CrossRefPubMed

88.

Wang L, Williamson SR, Wang M, et al. (2014) Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy. Mol Cancer 13:39. doi:10.1186/1476-4598-13-39 CrossRefPubMedPubMedCentral

89.

Kapur P, Pena-Llopis S, Christie A, et al. (2013) Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 14(2):159–167. doi:10.1016/s1470-2045(12)70584-3 CrossRefPubMedPubMedCentral

90.

Ho TH, Kapur P, Joseph RW, et al. (2016) Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Mod Pathol 29(1):34–42. doi:10.1038/modpathol.2015.123 CrossRefPubMedPubMedCentral

91.

Joseph RW, Kapur P, Serie DJ, et al. (2014) Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 120(7):1059–1067. doi:10.1002/cncr.28521 CrossRefPubMedPubMedCentral

92.

Joseph RW, Kapur P, Serie DJ, et al. (2016) Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol 195(1):180–187. doi:10.1016/j.juro.2015.07.113 CrossRefPubMed

Title: The spectrum of renal cell carcinoma in adults
Authors: Lakshmi Ananthakrishnan
Payal Kapur
John R. Leyendecker
Publication date: 01-06-2016
Publisher: Springer US
Published in: Abdominal Radiology / Issue 6/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-016-0737-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Renal cell carcinoma: staging and surveillance

The diffusion-weighted imaging of renal leiomyoma

The “beak” sign

CT-guided paravertebral block for microwave ablation of kidney tumors: a new technique

Percutaneous microwave ablation of T1a and T1b renal cell carcinoma: short-term efficacy and complications with emphasis on tumor complexity and single session treatment

Inherited renal carcinomas

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage